Related Experiment Video
Updated: Aug 15, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
[Antacids for postoperative prevention of stress ulcer in infants: a dose finding study]
Insights
Standard antacid dosages are too high for infants. A reduced dose of 0.25 ml/kg, given six times daily, effectively maintains gastric pH in infants undergoing cardiosurgery.
Area of Science:
- Pediatric Gastroenterology
- Neonatal Critical Care
- Pharmacology
Background:
- Infant gastric acid secretion increases exponentially in the first six months of life.
- Current antacid prophylaxis for stress ulcers in infants lacks age-specific dosage recommendations.
- Adult antacid dosages are inappropriate for pediatric use due to physiological differences.
Purpose of the Study:
- To evaluate optimal antacid dosing strategies for stress ulcer prophylaxis in infants.
- To compare the efficacy of two different antacid regimens in maintaining gastric pH.
- To inform evidence-based antacid dosage recommendations for neonates.
Main Methods:
- A crossover study involving 12 infants (4-174 days old) post-cardiosurgery.
- Continuous gastric pH monitoring over 48 hours with two 24-hour antacid regimens (A and B).
- Regimen A: 0.5 ml/kg every 4 hours; Regimen B: 0.25 ml/kg when pH < 3, checked every 30 minutes.
Main Results:
- Regimen B resulted in significantly lower mean administered antacid dose (2.2 ml) compared to Regimen A (12.0 ml).
- Regimen A achieved a higher mean gastric pH (median 5.96) than Regimen B (median 4.94).
- Lower pH (<3) was more frequent with Regimen B, but longer durations at this pH occurred with Regimen A.
Conclusions:
- Standard body weight-based antacid dosages appear excessive for infants.
- Reducing the single antacid dose to 0.25 ml/kg with frequent administration (6 times/day) is a reasonable approach for this age group.
- Further research into age-specific antacid dosing is warranted for effective stress ulcer prophylaxis in neonates.
Unlabelled:
In the prophylaxis of stress ulcers with antacids in young infants there are no recommendations of dosages that consider the physiologic maturation of gastric acid secretion. During the first six month of life the amount of gastric acid secretion in relation to body weight and body surface area increases exponentially. Therefore adult dosages of antacids cannot be transferred to infants.
Methods:
In a cross over study 12 infants aged between 4 and 174 days, who had been undergoing a cardiosurgical intervention with the heart lung machine, were treated during 48 hours with 2 different antacid regimens over a period of 24 hours each, monitoring the gastric pH continuously. The used antacid consisted of an aluminium-magnesium complex (Al(OH)3, 90 mg/ml and Mg(OH)2, 60 mg/ml): Regimen A: 6 x 0.5 ml per kg body weight. Regimen B: 0.25 ml per kg body weight at a gastric pH less than 3, with the pH read every 30 minutes.
Results:
Compared to 28 applications under regimen B, 72 single doses were given under regimen A, 58 of them at a gastric pH of higher than 3. Thus, the mean administered dose was significant lower under regimen B (2.2 ml) than under regimen A (12.0 ml). Consequently, the mean level of gastric pH was higher under regimen A (median: 5.96 +/- 1.31 versus 4.94 +/- 1.16). pH-values lower than 3 were more often measured under regimen B, whereas the phases at this pH-level were longer under regimen A.
Conclusion:
The usual body weight related dosage of antacids seems to be to high for early infancy. In the face of the discrepancy of the administered antacid quantity comparing regimen A with regimen B, it seems to be reasonable for the studied age group to reduce the single antacid dose to 0.25 ml/kg body weight while adhering to a high application frequency of 6 times a day.
More Related Videos
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease

